Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
earth1d
Human brains hold dormant viruses that come to life if you hit your head
The study reveals a potential link between concussions and the activation of dormant viruses, which may lead to ...
clinicaltrialsarena1d
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...
Breakthrough as scientists believe anti ageing vaccine ‘closer than ever’
Imagine a world where the mind remains sharp, even as the years pass by. Scientists are on the brink of a breakthrough that ...
Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region
Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Global Central Nervous System ...
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Viruses living your brain may 'wake up' to cause dementia, say experts
Studies have long warned that blows to the head may raise the risk of neurodegenerative conditions. Now, scientists believe ...
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
The Victoria Advocate2d
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...
Hosted on MSN3d
Herpes and Alzheimer's Tau; Dementia and Autism; Extended Paxlovid for Long COVID
A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...
Neuroscience News3d
Head Trauma May Reactivate Dormant Viruses, Increasing Alzheimer’s Risk
New research suggests that concussions and repetitive head trauma may reactivate dormant viruses like HSV-1 in the brain, potentially triggering neurodegenerative diseases such as Alzheimer’s.